{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15736", "batch_size": 200, "batch_pos": 107, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "'climbed' describes stock price movement, not the threat's impact using Q2 language.", "method": "llm_batch", "batch_id": "batch_2_20944", "batch_size": 200, "batch_pos": 80, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "'climbed 2.4%' involves a moderate verb and scale, but refers to financial metrics (shares), which is excluded by rule.", "method": "llm_batch", "batch_id": "batch_3_18352", "batch_size": 200, "batch_pos": 7, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_15444", "batch_size": 200, "batch_pos": 199, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports stock movement and potential funding deal but contains no explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_15400", "batch_size": 200, "batch_pos": 197, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_19372", "batch_size": 200, "batch_pos": 161, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_1484", "batch_size": 200, "batch_pos": 138, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "The segment describes potential funding for a trial, which is a development/capability aspect ('U.S. government is near a deal to fund a late-stage trial') without explicit calming language.", "method": "llm_batch", "batch_id": "batch_8_14456", "batch_size": 200, "batch_pos": 169, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
